Abstract 1832P
Background
According to Eurocare 6, the number of cancer survivors is increasing in Europe by 3,5% per year since 2010. Overall, 38% of all prevalent cases will live more than 10 years after the diagnosis. Colorectal cancer (CRC) stands as the 2nd most prevalent cancer among survivors across genders. Interestingly most CRC survivors will be older than 65 and will possibly need survivorship care services.
Methods
We investigated the cross-sectional association between physical-fitness, measured by the 6-minute walk test (6MWT), and isometric handgrip strength (IHS), and HRQoL (QLQ-C30 and QLQ-CR29) in a cohort of 272 Portuguese and Spanish CRC patients (mean age 65±10.8 years; 65% men; 10.5%, 21%, 33.6% and 28.7% in stages I, II, III and IV, respectively).
Results
Linear model analyses showed that greater performance in the 6MWT was associated with higher levels in several functional domains of QLQ-C30,such as physical scale (p=0.019), role (p<0.001), emotional (p=0.012), and cognitive function (p=0.012), and lower levels in several symptoms domains as fatigue (p=0.012), dyspnoea (p<0.001), insomnia (p=0.002) and appetite loss (p=0.001). Additionally, performance in 6MWT was associated with several functional domains of QLQ-CR29, as enhanced body image, less anxiety, and fewer weight problems (p=0.002, <0.001 and <0.001 respectively). Moreover, greater performance in IHS was associated with higher levels in role function (p<0.001) of QLQ-C30 and lower levels in several symptoms’ domains such as fatigue, pain, dyspnoea and insomnia (p<0.001, p=0.005, p=0.002 and p=0.014 respectively). Furthermore, performance in IHS was associated with several functional domains of QLQ-CR29, as improved body image, less anxiety, and fewer weight problems (p<0.001).
Conclusions
Our results suggest that greater aerobic fitness and upper-body muscle strength are associated with better functioning and lower symptomatology such as fatigue and pain. Additionally, greater aerobic fitness was associated with a better cognitive function. These findings support the need for rehabilitation strategies to enhance physical condition and quality of life in cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CIAFEL: (UIDB/00617/2020: https://doi.org/10.54499/UIDB/00617/2020 and UIDP/00617/2020: https://doi.org/10.54499/UIDP/00617/2020) ITR: LA/P/0064/2020.
Disclosure
A. Ruiz-Casado: Financial Interests, Personal, Invited Speaker: Abbott, MEDTRONIC, Nestle, Servier; Financial Interests, Personal, Advisory Board: Amgen, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1874P - Time to vomiting after chemotherapy in association with number of emetic risk factors among breast cancer patients receiving highly emetogenic chemotherapy
Presenter: Winnie Yeo
Session: Poster session 12
1875P - Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience
Presenter: Onur Bas
Session: Poster session 12
1877P - Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis
Presenter: Neha Pathak
Session: Poster session 12
1878P - Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial
Presenter: Aurélia JOUREAU-CHABERT
Session: Poster session 12
1879P - Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
Presenter: Arun Kumar Verma
Session: Poster session 12
1880P - Antiemetic prophylaxis during chemoradiation: Sub-study of the GAND-emesis trial identifying dosimetric predictors for vomiting
Presenter: Anika Johannsdottir
Session: Poster session 12
1881P - Enhancing chemotherapy-induced nausea and vomiting management: Insights into guideline adherence and patient outcomes
Presenter: Suresh Attili
Session: Poster session 12
1882P - Awareness of chemotherapy induced nausea and vomiting and adherence to guidelines: A multinational and multicenter survey
Presenter: Ricardo Caponero
Session: Poster session 12
1883P - Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial
Presenter: Emanuela Risi
Session: Poster session 12
1884P - Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM)
Presenter: Wendy Chan
Session: Poster session 12